There is an antidiabetic medication available on the U.S. market with an indication from the U.S. Food and Drug Administration (FDA) to prevent cardiovascular (CV) disease. A. True B. False Follow the link to see the answer!
Read More »Yearly Archives: 2017
Patient Communication
Do you use texting and/or email with your patients? Follow the link to see what your colleagues have to say!
Read More »April 18, 2017
I recently spent some time talking to the director of one of the transplant centers in Florida that specializes in liver and kidney transplants. She was explaining all the the factors that go into finding a correct match for patients, how patients who need a kidney are selected and how …
Read More »There Is A Difference
57-year-old female, prediabetes, class II obesity, arthritis R knee, family history includes father with type 2 diabetes with renal disease. Verbalizes her fear of having diabetes. Besides discussing lower carbohydrate meal plan, discussed metformin, and being as active as she possibly can without causing further injury to her knee. First set of labs showed her A1C to be 6.4% and her FPG 118.
Read More »Michael Hill Part 4, System Safety
In part 4 of this Exclusive Interview, Michael Hill explains the safety of the MiniMed 670G System and the results of the clinical trial, which included testing incidences of DKA and severe hypoglycemia requiring assistance.
Read More »Albuminuria Presentation Part 7, Treating Kidney Disease
In this week's Homerun Slides, determining therapeutic approaches for patients with type 2 and chronic kidney disease.
Read More »International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #71: Regulation of Glucose Metabolism in Liver Part 7 of 11
Allosteric regulation of hexose flux is another example where the regulation of gluconeogenesis occurs by interaction with glycolytic regulation. The conversion of F-1-P to F-1,6-P2 is irreversibly catalyzed by the gluconeogenic enzyme fructose-1,6- bisphosphatase, and the opposite glycolytic reaction is irreversibly catalyzed by phosphofructokinase.
Read More »April 15, 2017
This week, the AMA, in their journal, advised that they were in discussions to shift their focus from A1c and glucose readings as an indicator of successful diabetes management to a more cardiovascular outcomes and mortality data measurement of success. I am in total agreement that improving these numbers will …
Read More »A Major Shift in Diabetes Treatment Targets and Goals
Out with the old, in with the old and new?
Read More »Treating Diabetic Neuropathy
What treatments can improve pain and quality of life?
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.